PTAB challenges

Proceedings overview

There is one active AIA trial proceeding on file for US patent 10016284, which is currently pending. All claims of the patent remain untested by a final PTAB decision, which means the patent owner's claims are currently sustained, but their defensive posture is uncertain due to the ongoing challenge.

IPR2026-00216 — Medtronic, Inc. v. Moskowitz Family LLC

• Type: Inter Partes Review
• Filed: 2026-01-16
• Status: Pending. This proceeding is in the pre-institution phase, awaiting a decision from the Patent Trial and Appeal Board (PTAB) on whether to institute a trial.
• Judge panel: The judge panel information for this pending IPR is not yet publicly available.
• Petition grounds: The specific claims challenged, the prior art cited, and the statutory bases (§ 102 / § 103 / § 112) for the petition grounds are not publicly available through general search at this pre-institution stage.
• Institution decision: The institution decision has not yet been issued. The statutory deadline for the PTAB to issue a decision on institution is typically 6 months from the petition filing date, which would be approximately 2026-07-16.
• Final Written Decision: Not applicable, as the proceeding is currently pending institution.
• Settlement / termination: Not applicable, as the proceeding is currently pending institution.
• Appeal: Not applicable, as the proceeding is currently pending institution and no Final Written Decision has been issued.
• Defensive value: As this IPR is still in the pre-institution phase, its ultimate impact on the patent's claims is unknown. For a defendant facing assertion of this patent, the pending IPR creates uncertainty. If the IPR is instituted, it could lead to claim invalidation; however, until then, all claims remain valid and enforceable.

Strategic summary

Currently, all claims of US10016284 are untested by a final PTAB decision and are presumed valid. There is one pending Inter Partes Review, IPR2026-00216, filed by Medtronic, Inc. As this proceeding has not yet reached an institution decision, no claims have been canceled or sustained by the PTAB.

The estoppel landscape has not yet formed for this patent. Since no Final Written Decision has been issued, there are currently no estoppel implications under 35 U.S.C. § 315(e)(2) for the petitioner (Medtronic, Inc.) or their privies. All prior-art grounds remain potentially available for future challenges by other parties, as well as for Medtronic if the IPR is denied institution or if they were to pursue other avenues of challenge.

There are no discernible pattern signals regarding PTAB challenges for US10016284, as only one IPR proceeding has been filed against it to date. This single pending IPR does not indicate a history of aggressive PTAB appeals by the patent owner or involvement of defensive aggregators.

Recommended next steps

If you are a defendant, the most important next step is to closely monitor the progress of IPR2026-00216. Specifically, track the institution decision, which is expected by approximately 2026-07-16. This decision will be crucial as it determines whether the PTAB will proceed with a full trial on the challenged claims. You can typically find updates on the USPTO's PTAB E2E system by searching for IPR2026-00216.